Dayton T Brown Invests to Expand Capability and Accelerate Test Scheduling

Investing in the future of U.S. engineering and testing

Dayton T Brown, Inc. (DTB), today announced that it has invested $1.25 million in its laboratory in Bohemia, New York, to expand advanced testing capacity and position the Company for future growth in the aerospace, defense, and aviation markets.

With the expanded capability, DTB has addressed the increasingly stringent requirements of these growing markets while answering customer requests for faster turnaround times and flexible scheduling options.  The investment includes:

Self-contained, Walk-in Temperature and Humidity Test Chamber.  This addition augments current testing capability by adding a 10’ x 10’ x 10’, mid-size chamber option for customers, thereby increasing competitiveness and shortening lead times.  This new chamber performs MIL-STD-810 and DO-160 temperature and humidity testing with higher and lower temperature extremes and faster ramp rates, features needed for contemporary testing requirements for products such as electric vehicle batteries, engine assemblies, and military munitions and weapons.

Custom-Built Solar Chamber.  This provides a 12’ x 24’ x 10’ chamber designed to accommodate MIL-STD-810, ASTM, and ANSI testing specifications.  Specialized solar testing measures the effects of the light intensity generated when commercial or military products such as automotive parts, computer screens, or handheld electronics sit in the sun for an extended period, along with aiding in the understanding of the effects of solar activity on climate change.

Upgraded Vibration Facilities and Capabilities.  Several vibration tables have been reconfigured and upgraded, expanding DTB’s capacity for dynamics testing.  The Company has combined its Unholtz Dickie T1000s, MB Dynamics C150s, and temperature hoods with new vibration control computers.  This updated system allows DTB to meet a wider variety of test scheduling needs for the aerospace industry as well as the increased requirements of the Navy community.

Central Facility Hydraulic Power Supply.  This upgrade is composed of three hydraulic power supply systems which provide redundancy and capacity to support the laboratory and its growing testing needs.  The new power supplies are used to support DTB’s hydraulic, structural, and seismic testing capabilities, required for the growing aerospace market.

Scanning Electron Microscope.  Features like dispersive spectroscopy, a color chamber scope, and a stage navigation system, assist the Company’s growing need to perform engineering analysis and reverse engineering in support of service life extension programs (SLEP).

6-axis Portable Measurement Arm.  Specialized for high-accuracy probing, and flexible enough to be used nearly anywhere on the manufacturing floor, this tool helps to ease bottlenecks and reduce lead times.  This state-of-the-art measuring arm delivers real-time dimensional feedback at the point of production for interim and final product and fixture fabrication.  Improvements such as this enhance DTB’s recently expanded fabrication and machining center, offering customers in-house machining, tooling, and test fixture design and fabrication option to go along with engineering and test services.  One-stop-shopping leads to reduced turn-around times and streamlined scheduling for customers’ mission-critical programs.

“We continue to expand our capabilities and push the boundaries of innovation here on Long Island to remain the most comprehensive test facility able to supply all our customer’s testing needs under one roof,” commented Jim Kelly, President, Dayton T. Brown, Inc.  “We’re committed to responding to customer needs by advancing capabilities, increasing capacity, and providing flexibility to meet challenging schedules,” he continued.

Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Data from clinical studies of STK-001 demonstrated clinical benefit for patients ages 2 to 18 years old, including reductions in seizures and improvements in cognition and behavior that support the potential for disease modificatio. Analysis of 72 patients treated in STK-001 clinical trials suggests that higher STK-001 drug exposure in brain leads to greater seizure reductions. Two-year data from the longest prospective natural history study of Dravet syndrome showed that, on average, patients experienced no meaningful improvement in convulsive seizure frequency and exhibited widening gaps in cognition and behavior despite treatment with the best available anti-seizure medicines.
"Exact Sciences is looking forward to presenting new evidence at SABCS that adds important perspectives to treating breast cancer patients and showing that some patients may be able to de-escalate treatments and still have positive outcomes," said Dr. Rick Baehner, Chief Medical Officer, Precision Oncology, Exact Sciences. "Every year, we build upon the precedent set by the Oncotype DX Breast Recurrence Score® test and its prognostic and predictive abilities to determine the chemotherapy benefit for specific breast cancer patients. We are pleased to see authorities expanding access to this test as we continue to develop key evidence in collaboration with some of the world's most prestigious, breast cancer-focused organizations."
Clozapine has been established as the most effective antipsychotic medication for treatment-resistant schizophrenia. However, it is significantly underutilized mainly due to the risk of developing agranulocytosis and the need to frequently monitor the absolute neutrophil count (ANC).
Dagi-Ben Noon, CEO of Inspira Technologies, reflects on the partnership's significance: "By Integrating our technology to oxygenate blood directly with Ennocure's infection prevention solutions, we are focusing on potentially improving patient outcomes in ICUs and paving the way for safer, more effective life-support treatments. This collaboration is expected to accelerate the development and broaden the implementation of our advanced technology."
The findings suggest that the novel, non-invasive genomic test can help physicians guide next steps for these patients, enabling them to potentially avoid unnecessary invasive procedures or accelerate time to appropriate treatment.

By using this website you agree to accept Medical Device News Magazine Privacy Policy